Author | Silva, Cristiane França da | |
Author | Batista, Denise da Gama Jaen | |
Author | Batista, Marcos Meuser | |
Author | Lionel, Jessica | |
Author | Hammer, Erica Ripoll | |
Author | Brun, Reto | |
Author | Soeiro, Maria de Nazaré Correia | |
Access date | 2015-04-17T17:04:29Z | |
Available date | 2015-04-17T17:04:29Z | |
Document date | 2014 | pt_BR |
Citation | SILVA, Cristiane França da et al. In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi. Parasitology, n.141, p. 367-373, 2014. | pt_BR |
ISSN | 0031-1820 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/10057 | |
Language | eng | pt_BR |
Publisher | Cambridge University Press | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Doença de Chagas | pt_BR |
Subject in Portuguese | Tripanosoma Cruzi | pt_BR |
Subject in Portuguese | Quimioterapia | pt_BR |
Subject in Portuguese | Infecções por Protozoários | pt_BR |
Title | In vitro and in vivo activity of the chloroaryl-substituted imidazole viniconazole against Trypanosoma cruzi | pt_BR |
Type | Article | pt_BR |
DOI | 10.1017/S0031182013001601 | pt_BR |
Abstract | Chagas disease (CD) is caused by the intracellular protozoan parasite Trypanosoma cruzi and affects more than 10 million
people in poor areas of Latin America. There is an urgent need for alternative drugs with better safety, broader efficacy,
lower costs and shorter time of administration. Thus the biological activity of viniconazole, a chloroaryl-substituted
imidazole was investigated using in vitro and in vivo screening models of T. cruzi infection. Ultrastructural findings
demonstrated that the most frequent cellular damage was associated with plasma membrane (blebs and shedding events),
Golgi (swelling aspects) and the appearance of large numbers of vacuoles suggesting an autophagic process. Our data
demonstrated that although this compound is effective against bloodstream and intracellular forms (16 and 24 μM,
respectively) in vitro, it does not present in vivo efficacy. Due to the urgent need for novel agents against T. cruzi, the
screening of natural and synthetic products must be further supported with the aim of finding more selective and affordable
drugs for CD. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Affilliation | Swiss Tropical and Public Health Institute.Department of Medical Parasitology and Infection Biology. Basel, Switzerland. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil | pt_BR |
Subject | Chagas Disease | pt_BR |
Subject | Tripanosoma Cruzi | pt_BR |
Subject | Chloroaryl-substituted imidazole | pt_BR |
Subject | Viniconazole | pt_BR |
Subject | Chemotherapy | pt_BR |
Subject | In vitro | pt_BR |